908 Devices (NASDAQ:MASS) & Microbot Medical (NASDAQ:MBOT) Head to Head Analysis

Microbot Medical (NASDAQ:MBOT) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Volatility and Risk

Microbot Medical has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.

Institutional and Insider Ownership

16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 88.1% of 908 Devices shares are held by institutional investors. 4.7% of Microbot Medical shares are held by insiders. Comparatively, 28.2% of 908 Devices shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Microbot Medical and 908 Devices, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Microbot Medical	1	1	2	1	2.60
908 Devices	1	0	1	0	2.00

Microbot Medical currently has a consensus target price of $6.62, indicating a potential upside of 276.42%. 908 Devices has a consensus target price of $12.00, indicating a potential upside of 68.78%. Given Microbot Medical’s stronger consensus rating and higher possible upside, equities analysts clearly believe Microbot Medical is more favorable than 908 Devices.

Profitability

This table compares Microbot Medical and 908 Devices’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Microbot Medical	N/A	-21.84%	-20.71%
908 Devices	-62.40%	-14.03%	-10.40%

Earnings and Valuation

This table compares Microbot Medical and 908 Devices”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Microbot Medical	N/A	N/A	-$13.14 million	($0.26)	-6.77
908 Devices	$56.20 million	4.78	$19.49 million	($1.00)	-7.11

908 Devices has higher revenue and earnings than Microbot Medical. 908 Devices is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Microbot Medical beats 908 Devices on 8 of the 14 factors compared between the two stocks.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

About 908 Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.